About 1 million people became new GLP-1 users during that period in time, results show. Researchers classified them based on whether they had diabetes, obesity or some other related medical condition.

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

At the same time, the proportion of people using the drugs to control type 2 diabetes has declined Semaglutide is being used disproportionately by females, whites and people with obesity TUESDAY ...

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

"Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need to carefully ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

Study shows shift in GLP-1 drug use for obesity, not diabetes. Dennis Thompson, HealthDay News. Tue, July 23, 2024 at 5:58 PM UTC. 2 min read.